Balyasny Asset Management
IONS icon

Balyasny Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Balyasny Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-260,600
Closed -$20.6M – 3189
2025
Q4 		$20.6M Buy
260,600
+200
+0.1% +$15.1K 0.03% 701
2025
Q3 		$17M Buy
260,400
+400
+0.2% +$19.5K 0.02% 784
2025
Q2 		$10.3M Hold
260,000
– – 0.02% 960
2025
Q1 		$7.84M Buy
+260,000
New +$8.51M 0.01% 1045
2021
Q4 		– Sell
-130,000
Closed -$4.36M – 2417
2021
Q3 		$4.36M Sell
130,000
-105,500
-45% -$3.98M 0.02% 874
2021
Q2 		$9.39M Buy
+235,500
New +$9.22M 0.04% 538

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's IONS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 120,577 shares — an estimated $9.54M sold.

Balyasny Asset Management first reported a position in IONS in Q4 2015 and held it in 16 quarters. The position peaked at $51.3M in Q2 2024. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Balyasny Asset Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 120,577 Ionis Pharmaceuticals shares in Q1 2026, an estimated $9.54M.
  • Balyasny Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 16 quarters.
  • Balyasny Asset Management's Ionis Pharmaceuticals position peaked at $51.3M in Q2 2024.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.